NVS Novartis AG
USHealthcareAs of 2026-10-15
Why NVS matters now
Novartis AG (NVS) is a US stock in Healthcare. The latest InvestLog snapshot shows $150.35 with +2.36% on the session and $285.77B in market capitalization; recent performance reads 1-month -2.23% and YTD +6.68%.
The latest financial table shown here is Q1 2026, with revenue of $13.52B, net income of $3.16B, and EPS of $1.65. Investors can compare that operating picture with valuation signals such as P/E 21.32 and FCF yield 5.9%.
InvestLog's latest related AI research is a Material Company Event note titled "NVS receives FDA approval for as first treatment". The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $170.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
21.32
PEG
1.25
P/B
7.25
P/S
5.05
EV/EBITDA
14.37
DCF Value
$276.78
FCF Yield
5.9%
Div Yield
3.1%
Margins & Returns
Gross Margin
75.1%
Operating Margin
29.9%
Net Margin
24.3%
ROE
31.5%
ROA
11.3%
ROIC
14.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $13.52B | $3.16B | $1.65 |
| Q4 2025 | $13.33B | $2.41B | $1.25 |
| FY 2025 | $54.81B | $14.06B | $7.19 |
| Q3 2025 | $14.36B | $3.93B | $2.02 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$170.00
Target (Median)
$170.00
Target Range
$170.00 - $170.00
Related AI Research
NVS receives FDA approval for as first treatmentNovartis AG（NVS）的 as first treatment 获美国 FDA 批准
NVS receives FDA approval for as first treatment.Novartis AG（NVS）的 as first treatment 获美国 FDA 批准。
Morgan Stanley lowers NVS target to $156 from $170Morgan Stanley 下调目标价 诺华公司 (NVS)：$170 → $156
On 2026-10-06, Morgan Stanley lowered its NVS price target to $156 from $170 (-8.2%).Morgan Stanley 于 2026-10-06 将 NVS 目标价下调至 $156，此前为 $170，变动幅度 -8.2%。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
CH
Exchange
—
Beta
0.49
Novartis AG is a global healthcare enterprise dedicated to the discovery, development, production, and distribution of medical products across the world. The company operates through two main divisions: Innovative Medicines and Sandoz. Its Innovative Medicines segment provides prescription drugs to both patients and healthcare professionals, addressing a wide array of therapeutic areas such as ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory health, cardiovascular conditions, renal disorders, and metabolic diseases. The Sandoz division is responsible for the formulation, manufacturing, and commercialization of finished dosage form medicines. It also supplies active pharmaceutical ingredients and completed small molecule pharmaceuticals to other entities, in addition to offering retail generic drugs and anti-infectives. Furthermore, Sandoz provides crucial pharmaceutical intermediates and active ingredients, predominantly antibiotics, as well as protein- and biotechnology-derived products, including biosimilars, and offers biotechnology manufacturing services. Novartis AG also engages in strategic alliances, notably a licensing and collaboration deal with Alnylam Pharmaceuticals for the development, production, and marketing of inclisiran. Additionally, it holds a clinical partnership with Kura Oncology, Inc. to assess the combined efficacy of Tipifarnib and Alpelisib in patients diagnosed with head and neck squamous cell carcinoma. Founded in 1996, the company is headquartered in Basel, Switzerland.